LeMaitre Vascular (LMAT) Stock Forecast & Price Target

$86.51

+1.15 (+1.35%)

(As of 08/21/2024 ET)

LeMaitre Vascular - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 8 Analyst Ratings

Based on 8 Wall Street analysts who have issued ratings for LeMaitre Vascular in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 1 has given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for LMAT.

Consensus Price Target

$90.33
4.42% Upside

High Forecast	$105.00
Average Forecast	$90.33
Low Forecast	$70.00

According to the 8 analysts' twelve-month price targets for LeMaitre Vascular, the average price target is $90.33. The highest price target for LMAT is $105.00, while the lowest price target for LMAT is $70.00. The average price target represents a forecasted upside of 4.42% from the current price of $86.51.

Type	Current Forecast 8/23/23 to 8/22/24	1 Month Ago 7/24/23 to 7/23/24	3 Months Ago 5/25/23 to 5/24/24	1 Year Ago 8/23/22 to 8/23/23
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	2 Buy rating(s)
Hold	1 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$90.33	$77.57	$73.83	$69.33
Forecasted Upside	4.42% Upside	14.04% Upside	11.48% Upside	5.79% Upside

Get LeMaitre Vascular Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.

Ad Insiders Exposed

Has Trump Finally Gone Too Far?

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

LMAT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LMAT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

LeMaitre Vascular Stock vs. The Competition

Type	LeMaitre Vascular	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.75	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	4.42% Upside	5,586.21% Upside	8.75% Upside
News Sentiment Rating	Positive News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/20/2024	JMP Securities 2 of 5 stars		Boost Target	Market Outperform ➝ Market Outperform	$77.00 ➝ $100.00	+16.92%
8/2/2024	Barrington Research 4 of 5 stars		Boost Target	Outperform ➝ Outperform	$79.00 ➝ $92.00	+8.22%
8/2/2024	Lake Street Capital 3 of 5 stars		Initiated Coverage	Buy	$85.00 ➝ $105.00	+20.73%
5/31/2024	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Wittes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/31/2024	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$100.00	+26.95%
4/26/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$59.00 ➝ $75.00	+19.07%
2/6/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sector Weight
9/5/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$70.00	+26.61%
8/3/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$63.00 ➝ $67.00	+3.55%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:30 AM ET.

LMAT Forecast - Frequently Asked Questions

What is LeMaitre Vascular's forecast for 2024?: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for LeMaitre Vascular is $90.33, with a high forecast of $105.00 and a low forecast of $70.00.
Should I buy or sell LeMaitre Vascular stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There is currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LMAT shares.
Does LeMaitre Vascular's stock price have much upside?: According to analysts, LeMaitre Vascular's stock has a predicted upside of 19.24% based on their 12-month stock forecasts.
Has LeMaitre Vascular been upgraded by Wall Street analysts recently?: Over the previous 90 days, LeMaitre Vascular's stock had 1 upgrade by analysts.
What analysts cover LeMaitre Vascular?: LeMaitre Vascular has been rated by research analysts at Barrington Research, JMP Securities, Lake Street Capital, Roth Capital, and Roth Mkm in the past 90 days.
Do Wall Street analysts like LeMaitre Vascular more than its competitors?: Analysts like LeMaitre Vascular more than other "medical" companies. The consensus rating for LeMaitre Vascular is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LMAT compares to other companies.